Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Cintas Corp

Home Depot

Paycom Software

Tractor Supply

Ulta Beauty

With summer coming to an end, investors may want to target certain compelling stocks to buy now. Basically, the theory is the reverse of the adage, sell in May and go away.

Late-Summer Steals: 7 Stocks to Buy Before Fall

PayPal

Warner Bros Discovery Inc

ResMed aims to make devices that help people stay out of hospitals. Warner Bros.

3 Growth Stocks That Can Soar 50%, According to Wall Street

Keysight

Sealed Air

August has been a great month for investors looking for bargain stocks to buy on the dip. The S&P 500, Dow Jones Industrial Average, and the Nasdaq 100 were down 2,1%, 2.0%, and 2.4%, respectively, for the week of Aug. 14-18.

Buy the Drop: 3 Stocks to Snag After This Month's 20% Tumble

Autodesk

Coca-Cola

Mastercard

NIKE

In June, I introduced five stocks that AI predicted could double a portfolio in a year. Here's how they've done in the first month.

5 Blue-Chip Stocks AI Thinks Will Double Your Money by 2027

Parker-Hannifin

ResMed offers innovative solutions for people suffering from sleep apnea and other chronic diseases. Parker-Hannifin is a leader in motion control technologies and manufactures several related products.

2 Stocks That Could Grow Your Portfolio Over the Next Decade

ResMed (NYSE: RMD), a medical equipment company, has seen an 18% fall in a month, underperforming the broader S&P500 index, up 1%.

Here's Why We Think ResMed Stock Is Undervalued After An 18% Fall In A Month

Arbor Realty Trust

American States Water

Carlisle Companies

Duke Energy

Comfort Systems USA

Hershey

Hercules Capital

Hawkins

Kroger

Lindsay

Ryder System

Reinsurance Group of America

Reinsurnce Gr Amer Debentures 2016-15.06.56 Fixed/Floating Rate

Schwab US Dividend Equity ETF

J. M. Smucker

Target

Wingstop

Companies with a track record of increasing dividends usually perform better. Lists of upcoming dividend increases provide valuable insights for investors. Historical returns show that some companies outperformed the benchmark ETF.

17 Upcoming Dividend Increases, Including 2 Dividend Kings

ResMed (RMD) records a robust sales performance in fiscal Q4 backed by the ongoing combined availability of cloud-connected AirSense 10 and AirSense 11 sleep devices.

ResMed's (RMD) Q4 Earnings Miss, Revenues Beat Estimates

ResMed (RMD) came out with quarterly earnings of $1.60 per share, missing the Zacks Consensus Estimate of $1.67 per share. This compares to earnings of $1.49 per share a year ago.

ResMed (RMD) Misses Q4 Earnings Estimates

ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for ResMed (RMD)

ResMed (RMD) announces the acquisition of the Somnoware diagnostic management platform.

ResMed (RMD) Expands Solutions Portfolio With Somnoware Buyout

SAN DIEGO, July 06, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2023 on Thursday, August 3, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the acquisition of privately held Somnoware, a U.S. leader in sleep and respiratory care diagnostics software.

ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software

ResMed Inc., a leader in digital health and cloud-connected medical devices, is being considered as a potential addition to a healthcare portfolio due to its consistent financial performance and innovative product ecosystem. Despite a low yield and subdued dividend growth, the company's focus on fundamentally-driven growth, top-tier products addressing modern health issues, and strong moat make it an appealing investment. With a healthy balance sheet, accelerating free cash flow, and a reasonable valuation, ResMed could be a potential wealth compounder for decades to come.

Compound Your Wealth With ResMed

ResMed's (RMD) respiratory care business witnesses continued customer uptake of bilevel and other non-invasive ventilator solutions worldwide.

ResMed's (RMD) New Buyout Aids Growth Amid Rising Costs

INDIANAPOLIS, June 08, 2023 (GLOBE NEWSWIRE) -- People with heart failure and obstructive sleep apnea (OSA) can significantly reduce hospitalizations and ER visits as well as related costs by being adherent on positive airway pressure (PAP) therapy, according to two studies supported by ResMed (NYSE: RMD, ASX: RMD) and presented at SLEEP 2023.

PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP

Medical equipment name ResMed Inc (NYSE:RMD) is looking to snap a four-day win streak, down 0.3% at $221.33 at last glance.

Medical Equipment Stock to Add to Your Portfolio

SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023, beginning at approximately 9:20 a.m. (Pacific Daylight Time) at the Waldorf Astoria Monarch Beach in Dana Point, CA.

ResMed Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference

Zimmer Biomet Hlds

Investors interested in stocks from the Medical - Products sector have probably already heard of Zimmer Biomet (ZBH) and ResMed (RMD). But which of these two stocks offers value investors a better bang for their buck right now?

ZBH vs. RMD: Which Stock Should Value Investors Buy Now?

WASHINGTON, May 25, 2023 (GLOBE NEWSWIRE) -- Renowned medical experts at the American Thoracic Society International Conference unveiled new evidence that demonstrates treating obstructive sleep apnea (OSA) with positive airway pressure (PAP) therapy lowers all-cause mortality for patients. In addition, a late-breaking abstract showed treating central sleep apnea (CSA) caused a “significant and clinically relevant improvement” in their symptoms and quality of life. The studies were among 24 supported by ResMed (NYSE: RMD, ASX: RMD).

3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023

SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the appointment of two new executive team members: Michael Rider, Global General Counsel & Secretary, effective July 1, 2023, and Dawn Haake as ResMed's first Chief Quality Officer, effective May 1, 2023. Both joined ResMed's executive team on May 1 and report to the Office of the CEO.

ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer

Sleep-apnea device maker ResMed broke out after earnings, continuing its accelerating growth pace. The post Sleep-Apnea Growth Stock Breaks Out On Record Earnings; Device Sales Surge appeared first on Investor's Business Daily.

Sleep-Apnea Growth Stock Breaks Out On Record Earnings; Device Sales Surge

ResMed Inc. (RMD) Q3 2023 Earnings Call Transcript.

ResMed Inc. (RMD) Q3 2023 Earnings Call Transcript

ResMed (RMD) came out with quarterly earnings of $1.68 per share, beating the Zacks Consensus Estimate of $1.57 per share. This compares to earnings of $1.32 per share a year ago.

ResMed (RMD) Q3 Earnings and Revenues Beat Estimates

Year-over-year revenue grows 29%, operating profit up 28%, non-GAAP operating profit up 27% Year-over-year revenue grows 29%, operating profit up 28%, non-GAAP operating profit up 27%

News for ResMed Stock (RMD)